GSK’s systemic STING agonist could overcome delivery hurdles

By Mary Romeo | Nov 7, 2018 | 10:10 PM GMT

Editor's Note: This article was updated on Nov 9, 2018 at 12:05 AM GMT

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) researchers have developed a STING agonist that can be delivered systemically as opposed to intratumorally, which can overcome challenges of accessing hard to reach tumors or cancers that have